The ROE as of November 2024 (TTM) for MacroGenics, Inc. (MGNX) is -106.84%

According to MacroGenics, Inc.’s latest financial reports and current stock price. The company's current ROE is -106.84%. This represents a change of 156.55% compared to the average of -41.64% of the last 4 quarters.

MacroGenics, Inc. (MGNX) Historical ROE (quarterly & annually)

How has MGNX ROE performed in the past?

The mean historical ROE of MacroGenics, Inc. over the last ten years is -41.27%. The current -106.84% ROE has changed 158.89% with respect to the historical average. Over the past ten years (40 quarters), MGNX's ROE was at its highest in in the December 2017 quarter at 35.33%. The ROE was at its lowest in in the June 2024 quarter at -96.27%.

MacroGenics, Inc. (MGNX) ROE by Quarter and Year

Discovering the peaks and valleys of MacroGenics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

MacroGenics, Inc. (MGNX) Average ROE

How has MGNX ROE performed in the past?

The current ROE of MacroGenics, Inc. (MGNX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

MacroGenics, Inc. (MGNX) ROE vs. Peers

How is MGNX’s ROE compared to its peers?

MacroGenics, Inc.’s ROE is greater than Molecular Partners AG (-33.08%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than AN2 Therapeutics, Inc. (-54.72%), greater than Pharvaris N.V. (-36.89%), greater than PepGen Inc. (-62.74%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Tyra Biosciences, Inc. (-27.13%), greater than Century Therapeutics, Inc. (-65.37%), greater than Kezar Life Sciences, Inc. (-54.50%), greater than Nkarta, Inc. (-28.83%), greater than NGM Biopharmaceuticals, Inc. (-76.46%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Inozyme Pharma, Inc. (-68.93%), greater than Zentalis Pharmaceuticals, Inc. (-44.23%), greater than Syndax Pharmaceuticals, Inc. (-57.42%), less than Protagonist Therapeutics, Inc. (85.47%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Cullinan Oncology, Inc. (-28.37%),

Build a custom stock screener for MacroGenics, Inc. (MGNX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MacroGenics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MacroGenics, Inc. (MGNX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MacroGenics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.